In vivo expression of transforming growth factor-β1 in humans

Stimulation by cyclosporine

Gyu Tae Shin, Ashwani Khanna, Ruchuang Ding, Vijay K. Sharma, Milagros Lagman, Baogui Li, Manikkam Suthanthiran

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Background. Transforming growth factor-β1 (TGF-β1) is an immunoregulatory and fibrogenic cytokine. In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-β1 transcription rate in human T lymphocytes. Herein, we explored whether CsA augments the in vivo expression of TGF-β1 in humans. Methods. The inherent difficulty in studying the in vivo effect of CsA in humans was circumvented by investigating stable end-stage renal disease patients who were preconditioned with CsA before their living donor renal transplantation. Sera and peripheral blood mononuclear cells were obtained from CsA-pre-conditioned patients and quantified for TGF-β1 expression at the mRNA (by competitive polymerase chain reaction) and protein (sandwich enzyme-linked immunosorbent assay) levels. Results. Our studies demonstrated a significant increase in TGF-β1 expression after CsA therapy. The stimulatory effect was unique to TGF-β1, and CsA did not increase interleukin (IL)-10, IL-6, IL-2, or tumor necrosis factor-α expression. Conclusions. Our first-time demonstration of a TGF- β1 -selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-β1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.

Original languageEnglish
Pages (from-to)313-318
Number of pages6
JournalTransplantation
Volume65
Issue number3
DOIs
Publication statusPublished - 15 Feb 1998
Externally publishedYes

Fingerprint

Transforming Growth Factors
Cyclosporine
Immunosuppressive Agents
Cytokines
Living Donors
Interleukin-10
Kidney Transplantation
Immunosuppression
Chronic Kidney Failure
Interleukin-2
Interleukin-6
Blood Cells
Fibrosis
Tumor Necrosis Factor-alpha
Enzyme-Linked Immunosorbent Assay
Hypertension
T-Lymphocytes
Polymerase Chain Reaction
Messenger RNA
Serum

ASJC Scopus subject areas

  • Transplantation

Cite this

In vivo expression of transforming growth factor-β1 in humans : Stimulation by cyclosporine. / Shin, Gyu Tae; Khanna, Ashwani; Ding, Ruchuang; Sharma, Vijay K.; Lagman, Milagros; Li, Baogui; Suthanthiran, Manikkam.

In: Transplantation, Vol. 65, No. 3, 15.02.1998, p. 313-318.

Research output: Contribution to journalArticle

Shin, Gyu Tae ; Khanna, Ashwani ; Ding, Ruchuang ; Sharma, Vijay K. ; Lagman, Milagros ; Li, Baogui ; Suthanthiran, Manikkam. / In vivo expression of transforming growth factor-β1 in humans : Stimulation by cyclosporine. In: Transplantation. 1998 ; Vol. 65, No. 3. pp. 313-318.
@article{9f430d192c2841278f30c3588b30b715,
title = "In vivo expression of transforming growth factor-β1 in humans: Stimulation by cyclosporine",
abstract = "Background. Transforming growth factor-β1 (TGF-β1) is an immunoregulatory and fibrogenic cytokine. In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-β1 transcription rate in human T lymphocytes. Herein, we explored whether CsA augments the in vivo expression of TGF-β1 in humans. Methods. The inherent difficulty in studying the in vivo effect of CsA in humans was circumvented by investigating stable end-stage renal disease patients who were preconditioned with CsA before their living donor renal transplantation. Sera and peripheral blood mononuclear cells were obtained from CsA-pre-conditioned patients and quantified for TGF-β1 expression at the mRNA (by competitive polymerase chain reaction) and protein (sandwich enzyme-linked immunosorbent assay) levels. Results. Our studies demonstrated a significant increase in TGF-β1 expression after CsA therapy. The stimulatory effect was unique to TGF-β1, and CsA did not increase interleukin (IL)-10, IL-6, IL-2, or tumor necrosis factor-α expression. Conclusions. Our first-time demonstration of a TGF- β1 -selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-β1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.",
author = "Shin, {Gyu Tae} and Ashwani Khanna and Ruchuang Ding and Sharma, {Vijay K.} and Milagros Lagman and Baogui Li and Manikkam Suthanthiran",
year = "1998",
month = "2",
day = "15",
doi = "10.1097/00007890-199802150-00003",
language = "English",
volume = "65",
pages = "313--318",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - In vivo expression of transforming growth factor-β1 in humans

T2 - Stimulation by cyclosporine

AU - Shin, Gyu Tae

AU - Khanna, Ashwani

AU - Ding, Ruchuang

AU - Sharma, Vijay K.

AU - Lagman, Milagros

AU - Li, Baogui

AU - Suthanthiran, Manikkam

PY - 1998/2/15

Y1 - 1998/2/15

N2 - Background. Transforming growth factor-β1 (TGF-β1) is an immunoregulatory and fibrogenic cytokine. In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-β1 transcription rate in human T lymphocytes. Herein, we explored whether CsA augments the in vivo expression of TGF-β1 in humans. Methods. The inherent difficulty in studying the in vivo effect of CsA in humans was circumvented by investigating stable end-stage renal disease patients who were preconditioned with CsA before their living donor renal transplantation. Sera and peripheral blood mononuclear cells were obtained from CsA-pre-conditioned patients and quantified for TGF-β1 expression at the mRNA (by competitive polymerase chain reaction) and protein (sandwich enzyme-linked immunosorbent assay) levels. Results. Our studies demonstrated a significant increase in TGF-β1 expression after CsA therapy. The stimulatory effect was unique to TGF-β1, and CsA did not increase interleukin (IL)-10, IL-6, IL-2, or tumor necrosis factor-α expression. Conclusions. Our first-time demonstration of a TGF- β1 -selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-β1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.

AB - Background. Transforming growth factor-β1 (TGF-β1) is an immunoregulatory and fibrogenic cytokine. In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-β1 transcription rate in human T lymphocytes. Herein, we explored whether CsA augments the in vivo expression of TGF-β1 in humans. Methods. The inherent difficulty in studying the in vivo effect of CsA in humans was circumvented by investigating stable end-stage renal disease patients who were preconditioned with CsA before their living donor renal transplantation. Sera and peripheral blood mononuclear cells were obtained from CsA-pre-conditioned patients and quantified for TGF-β1 expression at the mRNA (by competitive polymerase chain reaction) and protein (sandwich enzyme-linked immunosorbent assay) levels. Results. Our studies demonstrated a significant increase in TGF-β1 expression after CsA therapy. The stimulatory effect was unique to TGF-β1, and CsA did not increase interleukin (IL)-10, IL-6, IL-2, or tumor necrosis factor-α expression. Conclusions. Our first-time demonstration of a TGF- β1 -selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-β1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.

UR - http://www.scopus.com/inward/record.url?scp=0032519407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032519407&partnerID=8YFLogxK

U2 - 10.1097/00007890-199802150-00003

DO - 10.1097/00007890-199802150-00003

M3 - Article

VL - 65

SP - 313

EP - 318

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -